Hangzhou's AnHeart Completes $14.6 Million A Funding
May 17, 2019

AnHeart Therapeutics of Hangzhou raised $14.6 million in a Series A round from Decheng Capital, a China life science investor. AnHeart uses its expertise in global clinical development to develop innovative products, which it partners at near-term value inflection points. In late 2018, AnHeart in-licensed global rights to an oral, highly selective ROS1/NTRK small molecule inhibitor from Daiichi Sankyo. AB-106 is in two Phase I clinical trials in the US and Japan. After the Phase I trial, AnHeart will assume responsibility for further clinical development.

The Phase I trials for AB-106 enrolled patients with solid tumors harboring either a ROS1 or NTRK fusion gene and neuroendocrine tumors. Daiichi Sankyo has reported preliminary safety and efficacy data from the first part of the US-based Phase 1/1b study at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Under the terms of the 2018 agreement, AnHeart made an upfront payment and is responsible for clinical, regulatory and sales milestone payments, as well as royalties on worldwide net sales. Financial details of the agreement were not disclosed.

AnHeart was founded in 2018.

About AnHeart Therapeutics

AnHeart Therapeutics is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of innovative medicines that improve human health and quality of life. AnHeart Therapeutics intends to optimize the commercial value of clinical assets by leveraging its strong capability of global clinical development and its access to an extensive network of experts across multiple disciplines. AnHeart Therapeutics is building a strong pipeline of innovative products by entering into partnering deals at near-term key value inflection points with large to medium biopharmaceutical companies.

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.